Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL Trial
09/2024
Journal Article
Authors:
Fong, Y.;
Dang, L.;
Zhang, B.;
Fintzi, J.;
Chen, S.;
Wang, J.;
Rouphael, N. G.;
Branche, A. R.;
Diemert, D. J.;
Falsey, A. R.;
Losada, C.;
Baden, L. R.;
Frey, S. E.;
Whitaker, J. A.;
Little, S. J.;
Kamidani, S.;
Walter, E. B.;
Novak, R. M.;
Rupp, R.;
Jackson, L. A.;
Yu, C.;
Magaret, C. A.;
Molitor, C.;
Borate, B.;
Babu, T. M.;
Kottkamp, A. C.;
Luetkemeyer, A. F.;
Immergluck, L. C.;
Presti, R. M.;
Backer, M.;
Winokur, P. L.;
Mahgoub, S. M.;
Goepfert, P. A.;
Fusco, D. N.;
Atmar, R. L.;
Posavad, C.;
Mu, J.;
Makowski, M.;
Makhene, M. K.;
Nayak, S. U.;
Roberts, P. C.;
Follmann, D.;
Gilbert, P. B.;
Coronavirus Variant Immunologic Landscape Trial Study, Team
Journal:
Clin Infect Dis
PMID:
39325506
URL:
https://www.ncbi.nlm.nih.gov/pubmed/39325506
Keywords:
COVID-19 booster Omicron correlate of risk exposure-proximal titer variant vaccine booster
Abstract:
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
